Home Compare BIIB vs SAN.PA
Stock Comparison · Industry comparison · Drug Manufacturers - General

Biogen vs Sanofi: Which Stock Looks Stronger in 2026?

Sanofi holds the cleaner structural position, with the lead spread across stability and growth. Biogen still has the edge on valuation, which keeps the comparison from looking entirely one-sided. In the market, Biogen carries the stronger setup — intact trend against Sanofi's broken trend. That leaves a split case: the structural lead stays with Sanofi, but the market is not currently confirming it.

The comparison is based on similar long-term financial trajectories, not sector labels.

Updated 2026-04-05

The clearest separation starts in stability, but growth adds another real layer to the result. The overall score gap is 20 points in favour of Sanofi.

INDUSTRY COMPARISON

Both operate in: Drug Manufacturers - General

This comparison is based on industry proximity, not on functional trajectory similarity. BIIB and SAN.PA share the same industry classification.

For a similarity-based comparison, see how Biogen and Sanofi each position within their functional peer groups in AssetNext.

Peer-Relative Score
BIIB
Biogen Inc.
26
Peer-Score
Signal qualityHigh
vs
SAN.PA
Sanofi
46
Peer-Score
Signal qualityHigh

Scores reflect position relative to comparable companies with similar long-term financial trajectories.

The largest gaps do not all point in the same direction.

Dimension spread: BIIB vs SAN.PA Profitability 0 16 Stability 10 67 Valuation 80 59 Growth 0 51 BIIB SAN.PA
Gap Ranking
#1 Stability +57
#2 Growth +51
#3 Valuation +21
#4 Profitability +16
Price Setup

Left means cheaper relative valuation. Higher means stronger structure.

Price setup map for BIIB and SAN.PA Stronger + cheaper Stronger + richer Weaker + cheaper Weaker + richer BIIBSAN.PA Relative valuation Structural strength

Sanofi occupies the cheaper side of the setup map, although Biogen Inc. still holds the stronger structural profile.

Valuation position uses peer-relative PE percentile (idx_pct_pe) where available.

Relative Position vs Comparable Companies
Stability
Sanofi ranks near the top of the group on stability; Biogen Inc. sits in the weaker half.
Growth
On growth, Sanofi is positioned higher in the group, while Biogen Inc. is closer to the middle.
Stability — Dominant Gap
BIIB
10
SAN.PA
67
Gap+57in favour of SAN.PA

The stability gap is very wide, with the stronger side looking materially steadier through time.

What keeps the gap from being one-sided

Biogen Inc. still shows lower market-fundamental divergence, which keeps the wider picture mixed rather than completely one-sided.

What this means for the comparison

The lead is built on both stability and growth — though valuation still provides a counterweight.

Explore full peer positioning in AssetNext

Break down the BIIB vs SAN.PA comparison across all dimensions with the full interactive tool.

Explore full breakdown →
Other comparisons with conflicting dimension signals

Explore how BIIB and SAN.PA each compare against other companies in their peer groups.

Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.

How AssetNext Peer Scores Work

AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.

Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.

Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.